Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11850699 | 0.82 | LMNA (0.70) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL7866855 | 0.80 | ENPP2 (0.52) | ALDH1A1MAPTLMNAKDM4EGAA | |
| Zinc Ion SCHEMBL1589972 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL6038801 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL67964 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL24810807 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL29618 | 0.78 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL84516 | 0.78 | CA2 (0.68) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL1589913 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL5153019 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 805 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110994-A1 | A PROCESS FOR THE PREPARATION OF LEDIPASVIR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-05-30 | — | — | WO | claimed |
| EP-3841101-B1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AG (DE) | 2023-05-03 | — | — | EP | claimed |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2023-02-23 | — | — | US | claimed |
| EP-4099991-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | Laurus Labs Limited (IN) | 2022-12-14 | — | — | EP | claimed |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | claimed |
| WO-2021156811-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | LAURUS LABS LIMITED (IN) | 2021-08-12 | — | — | WO | claimed |
| EP-3841101-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | Bayer Aktiengesellschaft (DE) | 2021-06-30 | — | — | EP | claimed |
| WO-2020039025-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | WO | claimed |
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PIRAMAL IMAGING SA (CH) | 2019-04-23 | — | — | US | claimed |
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2018-01-25 | — | — | US | claimed |
| CN-101835728-A | Compounds for imaging, diagnosing and/or treating central nervous system diseases or tumors | BAYER SCHERING PHARMA AG | 2010-09-15 | — | — | CN | claimed |
| EP-2217549-A2 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-08-18 | — | — | EP | claimed |
| WO-2010015387-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | claimed |
| WO-2010015340-A1 | DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-11 | — | — | WO | claimed |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | Lantheus Biosciences Ltd. (GB) | 2009-07-30 | — | — | US | claimed |
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2009-05-21 | — | — | US | claimed |
| WO-2009052970-A2 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-04-30 | — | — | WO | claimed |
| EP-2053033-A1 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | Bayer Schering Pharma AG (DE) | 2009-04-29 | — | — | EP | claimed |
| WO-2009033584-A2 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | claimed |
| EP-2036578-A1 | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022719-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ALDH1A1 2741/4885MAPT 80/4885LMNA 1871/4885 |
| US-10266506-B2 | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors | PMP22, MEN1, VHL | ALDH1A1 2741/4885MAPT 80/4885LMNA 1871/4885 |
| US-20230057246-A1 | NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR | CYP3A4, CYP4A11, CYP3A43 | ALDH1A1 553/4885MAPT 1832/4885LMNA 2938/4885 |
| US-20090191129-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ALDH1A1 2741/4885MAPT 80/4885LMNA 1871/4885 |
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | ADH1A, ADH5, FABP1 | ALDH1A1 67/4885MAPT 832/4885LMNA 2887/4885 |
| US-20210253573-A1 | METHOD FOR PREPARING 2-[(3R)-3-METHYLMORPHOLIN-4-YL]-4-[1-METHYL-1H-PYRAZOL-5-YL)-8-(1H-PYRAZOL-5-YL)-1,7-NAPHTHYRIDINE | CYP1B1, CYP4B1, CYP1A1 | ALDH1A1 432/4885MAPT 2788/4885LMNA 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.